Nearly 52.5 million people in the US have arthritis, according to an estimate from the CDC (Centers for Disease Control and Prevention).
Rheumatoid arthritis one of the most common types, and a new drug has just been approved to help make treatment easier. A new, extended-release form of Xeljanz (tofacitinib) recently received approval from the FDA to treat moderate to severe rheumatoid arthritis.
What is Xeljanz XR used for?
Xeljanz XR is recommended for adult patients with moderately to severely active rheumatoid arthritis—and who have had a poor response to methotrexate, or can no longer tolerate it. See More